<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006002</url>
  </required_header>
  <id_info>
    <org_study_id>10428</org_study_id>
    <secondary_id>UCCRC-10428</secondary_id>
    <secondary_id>UCCRC-NCI-49</secondary_id>
    <secondary_id>NCI-49</secondary_id>
    <nct_id>NCT00006002</nct_id>
  </id_info>
  <brief_title>SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy</brief_title>
  <official_title>A Phase II Trial of SU5416 (NSC# 686819) in Patients With Hormone Refractory Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: SU5416 may stop the growth of prostate cancer by stopping blood flow to the tumor.&#xD;
      Dexamethasone may be effective in slowing the growth of prostate cancer cells. It is not yet&#xD;
      known whether SU5416 or dexamethasone is more effective in treating progressive prostate&#xD;
      cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to compare the effectiveness of SU5416 with that of&#xD;
      dexamethasone in treating patients who have progressive prostate cancer that has not&#xD;
      responded to hormone therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the time to progression in patients with hormone refractory prostate cancer&#xD;
           treated with dexamethasone with or without SU5416.&#xD;
&#xD;
        -  Determine the differences in PSA kinetics and PSA hazard score between these two&#xD;
           regimens in this patient population.&#xD;
&#xD;
        -  Determine the objective response rate and time to development of new lesions in these&#xD;
           patients treated with SU5416.&#xD;
&#xD;
        -  Determine the toxicity of SU5416 in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are randomized to one of two treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral dexamethasone once a day 6 days a week. Treatment continues&#xD;
           until disease progression, at which time patients cross over to arm II.&#xD;
&#xD;
        -  Arm II: Patients receive oral dexamethasone as in arm I followed by SU5416 IV over 60&#xD;
           minutes twice weekly for 4 weeks. A smaller dose of dexamethasone is administered the&#xD;
           day after SU5416. Treatment continues for a minimum of 2 courses in the absence of&#xD;
           unacceptable toxicity or disease progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 60 patients (30 per arm) will be accrued for this study within&#xD;
      16 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">September 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dexamethasone followed by SU5416 done twice weekly (Monday and Thursday or Tuesday and Friday) every week for 4 weeks (a total of 8 doses). Four weeks of treatment (8 doses) is considered 1 cycle of treatment if tumor grows.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SU5416 done twice weekly (Monday and Thursday or Tuesday and Friday) every week for 4 weeks (a total of 8 doses). Four weeks of treatment (8 doses) is considered 1 cycle of treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaxanib</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed prostate cancer not amenable to curative treatment with&#xD;
             surgery or radiotherapy&#xD;
&#xD;
          -  Progressive disease defined by 1 of the following criteria:&#xD;
&#xD;
               -  New bone scan lesions&#xD;
&#xD;
               -  New or progressive radiologic lesions&#xD;
&#xD;
               -  Sequential increases in PSA on at least 2 successive measurements no less than 2&#xD;
                  weeks apart of at least 50% above nadir on prior therapy provided absolute value&#xD;
                  at time of enrollment is at least 5 ng/mL&#xD;
&#xD;
          -  Progressive disease, as defined above, despite adequate hormonal therapy defined by&#xD;
             all of the following:&#xD;
&#xD;
               -  Continued treatment with an LHRH agonist or prior orchiectomy&#xD;
&#xD;
               -  Sequential or concurrent treatment with an antiandrogen (e.g., flutamide,&#xD;
                  nilutamide, or bicalutamide)&#xD;
&#xD;
               -  Trial of antiandrogen withdrawal at least 4 weeks prior to study&#xD;
&#xD;
          -  CNS metastasis allowed if:&#xD;
&#xD;
               -  Previously treated&#xD;
&#xD;
               -  Neurologically stable&#xD;
&#xD;
               -  Oral or intravenous steroids or anticonvulsants not required&#xD;
&#xD;
               -  Brain scan (CT or MRI) within the past 2 weeks shows no active or residual&#xD;
                  disease&#xD;
&#xD;
                    -  Negative brain scan required if neurologic signs or symptoms suggestive of&#xD;
                       CNS metastasis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  WHO 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 75,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  Transaminases no greater than 2.5 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No uncompensated coronary artery disease&#xD;
&#xD;
          -  No history of myocardial infarction or severe unstable angina within the past 6 months&#xD;
&#xD;
          -  No severe peripheral vascular disease associated with diabetes mellitus&#xD;
&#xD;
          -  No deep venous or arterial thrombosis within the past 3 months&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No pulmonary embolism within the past 3 months&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No significant uncontrolled underlying medical or psychiatric illness&#xD;
&#xD;
          -  No serious active infection&#xD;
&#xD;
          -  No other prior or concurrent malignancy except nonmelanoma skin cancer unless&#xD;
             completed therapy and considered to be at less than 30% risk of relapse&#xD;
&#xD;
          -  No history of severe allergic or anaphylactic reactions to paclitaxel or docetaxel&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior systemic chemotherapy&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  No other concurrent investigational antineoplastic drugs&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter M. Stadler, MD, FACP</last_name>
    <role>Study Chair</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Center and Beckman Research Institute, City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center and Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033-0804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Medical Group</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louis A. Weiss Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Specialists of Central Illinois, S.C.</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evanston Northwestern Health Care</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ingalls Memorial Hospital</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LaGrange Memorial Hospital</name>
      <address>
        <city>LaGrange</city>
        <state>Illinois</state>
        <zip>60525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Hematology/Oncology</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology/Hematology Associates of Central Illinois, P.C.</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Illinois Hematology Oncology Center</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Medical Oncology and Hematology, Inc.</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46885-5099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michiana Hematology/Oncology P.C.</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Care Associates, P.L.L.C.</name>
      <address>
        <city>Saint Joseph</city>
        <state>Michigan</state>
        <zip>49085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Durham</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>August 28, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2003</study_first_posted>
  <last_update_submitted>September 4, 2013</last_update_submitted>
  <last_update_submitted_qc>September 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

